Azvudine is Effective in Reducing the Mortality of Severely and Critically Ill Patients with COVID-19, Revealed by a Latest Research

Recently, researchers from Shanghai uploaded a preprint to the preprint server medRxiv.

Title: Composite interventions on outcomes of severely and critically ill patients with COVID-19 in Shanghai, China

Background: The sixty-day effects of initial composite interventions for the treatment of severely and critically ill patients with COVID-19 are not fully assessed.

Method: Using a Bayesian piecewise exponential model, the research analyzed the 60-day mortality, health-related quality of life (HRQoL), and disability in 1082 severely and critically ill patients with COVID-19 between Dec. 8, 2022 and Feb. 9, 2023 in Shanghai, China. The final 60-day follow-up was completed on Apr. 10, 2023.

Results: Among 1082 patients (mean age: 78.0 years, 421 [38.9%] women), 139 patients (12.9%) died within 60 days. Azvudine had a 99.8% probability of improving 2-month survival (adjusted HR, 0.44 [95% credible interval, 0.24–0.79]) and Paxlovid had a 91.9% probability of improving 2-month survival (adjusted HR, 0.71 [95% credible interval, 0.44–1.14]) compared with the control. Azvudine, Paxlovid and therapeutic anticoagulation showed a significant reduction in disability (p < 0.05).

Conclusions: Among severely and critically ill patients with COVID-19 who received one or more therapeutic interventions, treatment with Azvudine had a 99.8% probability of improving 2-month survival compared with the control, while treatment with Paxlovid had a 91.9% probability, indicating that Azvudine was superior to Paxlovid. Treatment with Azvudine, Paxlovid and therapeutic anticoagulation could significantly reduce disability at day 60.

Full text:

https://www.medrxiv.org/content/10.1101/2023.05.10.23289325v3